Lexeo Therapeutics (LXEO) Non-cash Items (2022 - 2026)

Lexeo Therapeutics has disclosed Non-cash Items across 5 years of filings, most recently posting $2.8 million for Q1 2026.

• Non-cash Items for Q1 2026 came in at $2.8 million, up 481.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.8 million (up 481.05% YoY), and the FY2025 annual result was $2.6 million, down 10.33% from the prior year.
• Non-cash Items came in at $2.8 million for Q1 2026 at Lexeo Therapeutics, down from $11.3 million in the prior quarter.
• In the past five years, Non-cash Items ranged from a high of $20.1 million in Q4 2022 to a low of $475000.0 in Q1 2025.
• The 5-year median for Non-cash Items is $7.3 million (2023), against an average of $8.6 million.
• Across the five-year window, Non-cash Items sank 97.4% in 2025 and soared 481.05% in 2026, its largest moves.
• Lexeo Therapeutics' Non-cash Items stood at $20.1 million in 2022, then slumped by 32.0% to $13.7 million in 2023, then slumped by 79.17% to $2.9 million in 2024, then surged by 296.49% to $11.3 million in 2025, then tumbled by 75.58% to $2.8 million in 2026.
• The last three Non-cash Items figures came in at $2.8 million (Q1 2026), $11.3 million (Q4 2025), and $705000.0 (Q3 2025), per Business Quant data.